Business Context and Reporting Period
Company: Alnylam Pharmaceuticals, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: April 3, 2018
Event Date: March 28, 2018
Context: The Company entered into a Material Definitive Agreement with Agilent Technologies, Inc. regarding the commercial supply of its drug substance, patisiran.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on the terms of a new contractual agreement.
Material Changes and Agreement Details
On March 28, 2018, Alnylam and Agilent executed a Manufacturing Services Agreement for the commercial supply of patisiran active pharmaceutical ingredients (API). Key terms include:
- Scope: Agilent will manufacture and supply a specified percentage of the API required for commercial sale of patisiran.
- Ordering Mechanism: Alnylam must provide rolling quarterly forecasts. A portion of these forecasts constitutes a binding, firm order, adjustable after the first year of U.S. marketing authorization.
- Capacity Reservation: Agilent must reserve sufficient labor, materials, and equipment to meet firm orders and a percentage of non-binding forecasts, including a specified number of batches annually.
- Pricing and Payment: Pricing is determined per statement of work. Alnylam must make an initial payment for raw materials and resource reservation. Final payment occurs only after product acceptance.
- Term: Initial term of five years with automatic two-year renewal terms unless terminated.
- Termination Rights:
- 60 days' notice for Agilent's inability to perform, failure to maintain licenses/approvals, or material breach of business maintenance obligations.
- 30 days' notice if Alnylam determines patisiran is not commercially viable.
- Customary rights for material breach and bankruptcy.
Guidance, Outlook, and Risks
Management Commentary: The agreement is designed to secure commercial supply capacity for patisiran. The Company expects to file the full agreement as an exhibit to its Form 10-Q for the quarter ended March 31, 2018.
Risks and Contingencies: The agreement is subject to conflicting obligations under third-party agreements. Termination may incur penalties in certain instances. The arrangement relies on Agilent's ability to maintain Good Manufacturing Practices (cGMP) and necessary regulatory approvals.
Investor Verification Checklist
- Verify the specific percentage of patisiran API supply allocated to Agilent in the full agreement text.
- Review the Form 10-Q for the quarter ended March 31, 2018, for the complete agreement exhibit and any financial impact disclosures.
- Assess the impact of the initial payment for raw materials on the Company's near-term cash flow.
- Monitor the timeline for U.S. marketing authorization to understand when firm order adjustments will occur.
- Confirm Agilent's current regulatory status and capacity to meet the reserved batch requirements.